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Abstract
Background: To investigate differences in the performance of the Finnish Diabetes Risk Score (FINDRISC) as a
screening tool for glucose abnormalities after shifting from glucose-based diagnostic criteria to the proposed new
hemoglobin (Hb)A1c-based criteria.
Methods: A cross-sectional primary-care study was conducted as the first part of an active real-life lifestyle
intervention to prevent type 2 diabetes within a high-risk Spanish Mediterranean population. Individuals without
diabetes aged 45-75 years (n = 3,120) were screened using the FINDRISC. Where feasible, a subsequent 2-hour oral
glucose tolerance test and HbA1c test were also carried out (n = 1,712). The performance of the risk score was
calculated by applying the area under the curve (AUC) for the receiver operating characteristic, using three sets of
criteria (2-hour glucose, fasting glucose, HbA1c) and three diagnostic categories (normal, pre-diabetes, diabetes).
Results: Defining diabetes by a single HbA1c measurement resulted in a significantly lower diabetes prevalence
(3.6%) compared with diabetes defined by 2-hour plasma glucose (9.2%), but was not significantly lower than that
obtained using fasting plasma glucose (3.1%). The FINDRISC at a cut-off of 14 had a reasonably high ability to
predict diabetes using the diagnostic criteria of 2-hour or fasting glucose (AUC = 0.71) or all glucose abnormalities
(AUC = 0.67 and 0.69, respectively). When HbA1c was used as the primary diagnostic criterion, the AUC for
diabetes detection dropped to 0.67 (5.6% reduction in comparison with either 2-hour or fasting glucose) and fell
to 0.55 for detection of all glucose abnormalities (17.9% and 20.3% reduction, respectively), with a relevant
decrease in sensitivity of the risk score.
Conclusions: A shift from glucose-based diagnosis to HbA1c-based diagnosis substantially reduces the ability of
the FINDRISC to screen for glucose abnormalities when applied in this real-life primary-care preventive strategy.
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Background
Type 2 diabetes is a significant preventable disease and a
growing public-health problem. When planning diabetes-
prevention measures, people at risk for the disease should
be targeted with lifestyle-modification interventions
through a stepwise high-risk approach tailored to the
specific local situation [1]. Simple prediction tools that can
identify at-risk individuals could reduce the cost and
inconvenience of screening. With such tools, a two-step
procedure could be used: first, patients would be screened
with a risk score; and second, those individuals identified
to have a high risk for diabetes, would have their glycemic
status assessed by measuring fasting plasma glucose
(FPG), either alone or along with 2-hour post-load glucose
(2hPG) using the oral glucose tolerance test (OGTT), or
the more recently authorized hemoglobin (Hb)A1c
measurement [2-4].
The notion that diabetes development can be prevented
or delayed by intensive lifestyle intervention is not new
[5,6]. However, it has recently been suggested that
progression to diabetes can be also delayed by intensive
intervention when applied to real-life primary health care
of high-risk subjects identified first with the simple Finnish
Diabetes Risk Score (FINDRISC) tool [7]. If such a risk
score can be shown to have general applicability, it could
provide a rational basis to decide which patients might
benefit from intensive lifestyle intervention [8]. Thus,
community-based evaluations are essential in order to
learn about the FINDRISC feasibility and performance to
screen for current and future glucose disorders.
The present study aimed at assessing possible differences
in the performance of the FINDRISC as a screening tool for
glucose abnormalities after shifting from the previously
agreed 2hPG and FPG diagnostic criteria to the new
HbA1c criteria in a real-life primary healthcare strategy to




The research ethics committee board at the Jordi Gol
Research Institute (Barcelona, Spain) approved the proto-
col, and all participants gave written informed consent.
Training, data sources, and study participants
The methods described for the active public-health pro-
gram, DE-PLAN (Diabetes in Europe-Prevention using
Lifestyle, Physical Activity and Nutritional intervention),
which was developed in Catalonia (DE-PLAN-CAT),
were used for this study [9]. All participating profes-
sionals were certified before recruitment, after attending
several training meetings.
White Europeans without diabetes aged 45-75 years
were evaluated by general practitioners in 18 primary
healthcare centers. These participating centers were
selected in a stratified manner, and covered all primary-
care services for 315,703 inhabitants (4.5% of the popula-
tion in Catalonia). The participants were consecutively
recruited from a random list of the computerized public-
healthcare system to obtain a representative sample of the
population assigned to each center. For the associated
lifestyle intervention study (at least 5-year follow-up of the
screened subjects) all individuals with conditions such as
severe psychiatric disease (for example, such as bipolar
disorder or psychosis), chronic kidney disease (severe
chronic renal failure) and serious chronic liver disease, or
blood disorders (for example, severe iron-deficiency ane-
mia or other conditions that might interfere with the
HbA1c measurement), were excluded from the study.
The first screening used the Spanish version of the FIN-
DRISC, a well-validated, eight-item European question-
naire related to diabetes risk factors to characterize
subjects according to their future risk of type 2 diabetes.
The most recent version was used, and ranged from 0 to
26 points, as follows: <7 points (low), 7 to 11 (slightly
increased), 12 to 14 (moderate), 15 to 20 (high), and over
20 (very high) [10]. Both the questionnaire and the Eur-
opean guidelines recommend that scores of 15 or higher
should prompt blood tests for diabetes [9-12]. The ques-
tionnaire collected information about age, sex, weight and
height (to calculate body mass index; BMI), waist circum-
ference, use of concomitant blood-pressure medication,
history of high blood glucose disorders, physical activity,
family history of diabetes, and daily consumption of
vegetables, fruits and berries. Body weight and height were
measured in light clothing, without shoes. Waist circum-
ference was measured midway between the lowest rib and
the iliac crest. Anthropometric parameters were deter-
mined by trained nurses.
The second screen involved use of a 2-hour 75-g OGTT,
in accordance with the World Health Organization
(WHO) standards, along with measurements of FPG and
2hPG, carried out in all recruiting centers. All participants
with FINDRISC scores of 15 or over were asked to
undergo a screening OGTT as part of the protocol.
Participants with FINDRISC scores below 15 were also
offered an OGTT if they wished [7]. For this part of the
DE-PLAN-CAT project (screening), diagnosis of all glu-
cose disorders was based on the results of a single OGTT.
Any volunteer with either a FPG or 2hPG result suggestive
of diabetes was excluded from participation in the subse-
quent part of the project (lifestyle intervention). A second
OGTT to confirm the diagnosis of diabetes was recom-
mended in the study protocol for those individuals who
did ultimately participate in the lifestyle intervention.
Plasma glucose level was determined by a uniform
glucose oxidase-peroxidase method. HbA1c determination
was performed at the same time, using a standardized
Costa et al. BMC Medicine 2013, 11:45
http://www.biomedcentral.com/1741-7015/11/45
Page 2 of 12
high-performance liquid chromatography (HPLC) assay
aligned to the Diabetes Control and Complications Trial
in all laboratories [13]. Blood samples were analyzed using
similar techniques at five laboratories, four of which were
based in the same institution (Catalan Health Institute).
The intra-assay and interassay coefficients of variation for
all assays ranged from 2 to 3%.
Three main diagnostic categories (normal, pre-diabetes
and diabetes) were defined using the WHO criteria based
on 2hPG (less than 7.8, 7.8 to 11.0 mmol/l and greater or
equal than 11.1 mmol/l) and/or FPG (6.1 to 6.9 mmol/l);
the American Diabetes Association (ADA) criteria based
on FPG (less than 5.5, 5.5 to 6.9, and greater or equal than
7.0 mmol/l); and the new proposed HbA1c criteria (less
than 38, 38 to 48, and greater than 48 mmol⁄mol) or (less
than 5.7, 5.7 to 6.4, and greater than 6.4%). The diagnostic
categories derived from these alternative approaches were
compared with the FINDRISC test scores and risk classes
in order to investigate the capability of the questionnaire
in classifying individuals according to their current glyce-
mic status.
Statistical analysis
The sample size calculation details using available data on
diabetes incidence in the high-risk Catalan population
have been published previously [7]. Assuming that the
population to be screened were able to accept the proposal
to participate in the subsequent lifestyle intervention
phase, we calculated that the study needed at least 1,650
people in the screening period (type 1 and type 2 errors:
5% and 20%, respectively). Multiple comparisons of the
significant differences between groups were carried out by
one-way ANOVA, and/or by Student’s t-test for continu-
ous variables and the c2 test for categorical variables. The
main results are presented using the WHO criteria as the
current standard, compared with the ADA criteria and the
new HbA1c criteria.
Given the stratification of the sample, a pooled analysis of
all questionnaires was conducted. Sensitivity, specificity,
and predictive values were calculated for different cut-off
points of the FINDRISC test and for different sets of
diagnostic criteria. The positive and the negative predictive
values (PPV and NPV) and respective likelihood ratios
(LRs) were also calculated. The 95% confidence interval
(CI) for sensitivity, specificity, predictive values, and LRs
was estimated. To determine the performance of the
questionnaire and the optimal FINDRISC cut-off point for
the detection of diabetes and all glucose abnormalities (dia-
betes and pre-diabetes), the receiver operating characteris-
tic (ROC) curves were calculated by plotting the sensitivity
of the test versus the false-positive rate (1 minus specificity).
The optimal cut-off points used were the peaks of the
curve, where the sum of sensitivity and specificity is at
maximum. The area under the ROC curve (AUC) with its
95% CI was used to compare results between the three sets
of diagnostic criteria based on 2hPG, FPG and HbA1c,
respectively. Statistical analyses were conducted using SPSS
for Windows (version 15.0; SPSS Inc., Chicago, IL, USA).
Results
In all, 3,647 subjects were invited to participate (79% by
direct contact and 21% by phone) of whom 3,120 (85.5%)
accepted the invitation to the first screening session,
which used the FINDRISC. In this group, 65.5% were
women, the mean age was 60.1 years, and the mean BMI
was 28.8 kg/m2. Most of the FINDRISC questionnaires
were filled in by the healthcare providers during the first
interview (95%), but a small number were self-adminis-
tered (5%). The main characteristics of the participants in
this first step including their FINDRISC findings are
reported in Table 1. Given the usually recommended cut-
off point of 15, the questionnaire identified 40 individuals
(26.9%) as having high or very high risk of diabetes.
Of the original 3,120 participants in the first screen,
1,746 participants (56%) also authorized the second
screening session, using blood tests; of these, 1,712 (54.9%)
cases had all requested data available. In this group, 66.8%
were women, the mean age was 60.7 years, and the mean
BMI was 29.7 kg/m2. The characteristics of the partici-
pants in this second step, including glucose and HbA1c
diagnostic findings, are reported in Table 2. In all, 723
individuals (42.2%) who underwent blood testing had been
previously classified by the questionnaire as having high or
very high risk of diabetes. We found no significant differ-
ence in the FINDRISC items between subjects who
accepted or rejected the blood test. The risk of diabetes
assessed by the FINDRISC score was higher in women,
whereas the risk of diabetes assessed by either the glucose
or the HbA1c measurements was higher in men.
The diagnostic categories by the WHO criteria (which
includes 2hPG) were 1,174 (68.6%; 95% CI 66.3 to 70.8)
individuals with normal glucose tolerance, 380 (22.2%;
95% CI 20.2 to 24.2) with pre-diabetes, and 158 (9.2%; 95%
CI 7.9 to 10.7) with diabetes. The corresponding FPG-
based findings (ADA criteria) were 1,227 (71.7%; 95%
CI 69.5 to 73.8) with normal fasting glucose, 432 (25.2%;
95% CI 23.2 to 27.4) with pre-diabetes, and 53 (3.1%; 95%
CI 2.3 to 4.0) with diabetes. Findings based on HbA1c
were 1,221 (71.3%; 95% CI 69.1 to 73.4) with normal
HbA1c, 429 (25.1%; 95% CI 23.0 to 27.2) with pre-dia-
betes, and 62 (3.6%; 95% CI 2.8 to 4.6) with diabetes.
Figure 1 summarizes both of the screening phases and the
participant distribution by test results and diagnostic
criteria. Of the subgroup of subjects identified as being
high or very high risk (n = 723) by the FINDRISC, the
2hPG, FPG, and HbA1c tests indicated 29.2%, 36.4%, and
25.8%, respectively as having pre-diabetes and 15.2%, 5.0%,
and 5.9% as having diabetes. Meanwhile, these findings
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were 17.1%, 17.1%, and 24.6%, respectively, for pre-dia-
betes and 4.8%, 1.7%, and 1.9% for diabetes in the indivi-
duals identified by the FINDRISC as having low, slightly
increased, or moderate risk (n = 989).
Mean FINDRISC values showed a progressive and
significant increase (P<0.01) as the glucose-metabolism
categories worsened (normal, pre-diabetes, diabetes),
regardless of the set of diagnostic criteria applied, whether
2hPG, FPG, or HbA1c (Table 3). Thus, we found a strong
correlation between FINDRISC classes and either the glu-
cose or the HbA1c values, and this tended to increase
dramatically with increasing FINDRISC scores (Figure 2).
Likewise, individuals with higher scores had higher values
for age, BMI, waist circumference, and systolic and diastolic
blood pressure (Table 3). No significant differences
between the recruiting centers regarding the FINDRISC
test scores or the distribution of the risk classes were found.
The ROC curves for detecting unknown diabetes and
any other degree of abnormal glucose metabolism (dia-
betes and pre-diabetes) in the studied sample by the
diagnostic criteria applied were calculated (Figure 3).
Table 4 shows the FINDRISC findings (sensitivity, speci-
ficity, and predictive values) using different cut-off
points for screen-detected diabetes and overall glucose
metabolic abnormalities, allowing for all diagnostic cri-
teria. The ROC curves indicated that a cut-off of 14 for
detecting glucose-metabolism abnormalities offered the
best balance between true-positive and false-positive
rates in this population, irrespective of the set of diag-
nostic criteria used.
Drawing on this cut-off point of greater than or equal to
14 on the FINDRISC scale, and regarding the diagnostic
classification by the WHO criteria (which includes 2hPG),
we found that the AUC for detecting unknown diabetes
(Figure 3A) was 0.67 (95% CI 0.59 to 0.72) for men and
0.76 (95% CI 0.70 to 0.81) for women. The corresponding
values for all glucose abnormalities (Figure 3B) were 0.64
(95% CI 0.60 to 0.69) for men and 0.70 (95% CI 0.66 to
0.73) for women. The sensitivity and specificity were 75.9%
and 52.3% for the detection of type 2 diabetes alone, and
65.8% and 56.7% for detecting any degree of abnormal glu-
cose metabolism. The cut-off point of 14 had an NPV of
95.5% for diabetes and 78.4% for glucose abnormalities
(Table 4).
For FPG, the corresponding values (ADA criteria) for
diabetes (Figure 3C) were 0.72 (95% CI 0.63 to 0.82) for
men and 0.70 (95% CI 0.61 to 0.79) for women. Equivalent
values for all glucose metabolic abnormalities (Figure 3D)
were 0.64 (95% CI 0.60 to 0.69) and 0.73 (95% CI 0.69 to
0.76), respectively. For a FINDRISC greater or equal to 14,
the sensitivity and specificity were 75.5% and 50.5%,
respectively, for the detection of diabetes, and 68.0% and
56.6%, respectively, for detecting glucose abnormalities.
The NPVs were 98.5% and 81.8%, respectively (Table 4).
Table 1 Characteristics of the participants in the first screening step (n = 3,120) by sex including Finnish Diabetes Risk
Score (FINDRISC) findings
Parameter Overall Male Female p
Number of participants, n 3120 1077 (34.5) 2043 (65.5) -
Age, years 60.1 ± 8.3 61.3 ± 8.3 59.5 ± 8.2 <0.01
45 to 54 941 (30.2) 275 (25.5) 666 (32.6)
55 to 64 1157 (37.1) 377 (35.0) 780 (38.2)
>65 1022 (32.8) 425 (39.5) 597 (29.2)
BMI, kg/m2 28.8 ± 4.6 28.7 ± 4.0 28.9 ± 4.9 0.38
<25 612 (19.6) 185 (17.2) 427 (20.9)
25 to 30 1464 (46.9) 555 (51.5) 909 (44.5)
≥30 1044 (33.5) 337 (31.3) 707 (34.6)
Waist circumference, cm 95.6 ± 11.5 100.0 ± 10.0 93.4 ± 11.6 <0.01
M <94, F <80 517 (16.6) 256 (23.8) 261 (12.8)
M 94 to 102, F 80 to 88 942 (30.2) 402 (37.7) 540 (26.4)
M ≥103, F ≥89 1661 (53.2) 419 (38.9) 1242 (60.8)
Systolic blood pressure, mmHg 131.7 ± 15.4 134.0 ± 14.7 130.5 ± 15.7 <0.01
Diastolic blood pressure, mmHg 78.2 ± 10.6 79.0 ± 9.3 77.8 ± 11.1 <0.01
FINDRISC, points 11.8 ± 4.5 11.4 ± 4.4 12.0 ± 4.6 <0.01
Low risk (<7) 346 (11.1) 136 (12.6) 210 (10.3)
Slightly increased risk (7 to 11) 1221 (39.1) 441 (40.9) 780 (38.2)
Moderate risk (12 to 14) 713 (22.9) 235 (21.8) 478 (23.4)
High risk (15 to 20) 741 (23.8) 244 (22.7) 497 (24.3)
Very high risk (>20) 99 (3.2) 21 (1.9) 78 (3.8)
aData are means ± SE for quantitative variables or n (%) for qualitative variables.
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Finally, parallel findings based on HbA1c for diabetes
(Figure 3E) were 0.62 (95% CI 0.53 to 0.70) for men and
0.70 (95% CI 0.61 to 0.80)] for women. The correspond-
ing values for all glucose metabolic abnormalities
(Figure 3F) were 0.51 (95% CI 0.46 to 0.57) and 0.57
(95% CI 0.53 to 0.61), respectively. For a cut-off point of
14, the sensitivity and specificity were 74.2% and 50.5%,
respectively, for the detection of diabetes, and 54.4% and
51.3% respectively, for detecting glucose abnormalities.
The corresponding NPVs were 98.1% and 73.6%, respec-
tively (Table 4).
Discussion
Screening for diabetes and prevention programs
The growing prevalence of type 2 diabetes requires the
development and introduction of better prevention
strategies to reduce the incidence and prevalence of the
disease [14]. Regrettably, diabetes prevention has not been
prioritized worldwide, despite clear evidence that not
including these policies results not only in health costs,
but also other costs to society. Although the development
of specific preventive measures for diabetes that target the
entire population is not an appropriate strategy, it is essen-
tial to identify subjects at increased risk; consequently, a
simple, inexpensive, non-invasive and valid tool focused
on classic and valuable risk factors is needed [8].
It is currently recommended that screening for dia-
betes and pre-diabetes should be carried out using a risk
score, followed by conventional diagnosis in those indi-
viduals identified as being at high risk. HbA1c is a good
marker of protein glycation secondary to long-term
exposure to glucose, but until recently, it had not been
Table 2 Characteristics of the participants in the second screening step (n = 1,712) by sex including Finnish Diabetes
Risk Score (FINDRISC), glucose and hemoglobin (Hb)A1c findings
Parameter Overall Male Female p
Number of participants (n) 1712 569 (33.2) 1143 (66.8) -
Age, years 60.7 ± 8.2 62.4 ± 8.1 59.8 ± 8.1 <0.01
45 to 54 464 (27.1) 124 (21.8) 340 (29.7)
55 to 64 640 (37.4) 187 (32.9) 453 (39.6)
>65 608 (35.5) 258 (45.3) 350 (30.6)
BMI, kg/m2 29.7 ± 4.7 29.5 ± 3.9 29.7 ± 5.1 0.43
<25 240 (14.0) 59 (10.4) 181 (15.8)
25 to 30 740 (43.2) 274 (48.2) 466 (40.8)
≥30 732 (42.8) 236 (41.5) 496 (43.4)
Waist circumference, cm 97.4 ± 11.5 102.0 ± 9.8 95.2 ± 11.6 <0.01
M <94, F <80 193 (11.3) 87 (15.3) 106 (9.3)
M 94 to 102, F 80 to 88 463 (27.0) 205 (36.0) 258 (22.6)
M ≥103, F ≥89 1056 (61.7) 277 (48.7) 779 (68.2)
Systolic blood pressure, mmHg 132.6 ± 15.5 135.0 ± 14.8 131.5 ± 15.7 <0.01
Diastolic blood pressure, mmHg 78.8 ± 11.4 79.2 ± 9.4 78.6 ± 12.4 0.33
FINDRISC, items 13.5 ± 4.4 13.2 ± 4.2 13.7 ± 4.5 0.04
Low risk (<7) 98 (5.7) 29 (5.1) 69 (6.0)
Slightly increased risk (7 to 11) 475 (27.7) 174 (30.6) 301 (26.3)
Moderate risk (12 to 14) 416 (24.3) 135 (23.7) 281 (24.6)
High risk (15 to 20) 633 (37.0) 212 (37.3) 421 (36.8)
Very high risk (>20) 90 (5.3) 19 (3.3) 71 (6.2)
2-hour Plasma glucose, mmol/l 6.8 ± 2.8 7.4 ± 3.0 6.6 ± 2.7 <0.01
Diabetes 158 (9.2) 70 (12.3) 88 (7.7)
Pre-diabetes 380 (22.2) 167 (29.3) 213 (18.6)
Fasting plasma glucose, mmol/l 5.2 ± 1.0 5.4 ± 1.1 5.1 ± 1.0 <0.01
Diabetes 53 (3.1) 22 (3.9) 31 (2.7)
Pre-diabetes 432 (25.2) 189 (33.2) 243 (21.3)
HbA1c (NGSP),%b 5.5 ± 0.6 5.5 ± 0.6 5.5 ± 0.6 0.26
HbA1c (IFCC), mmol/mol 36.3 ± 6.4 36.6 ± 6.7 36.2 ± 6.3 0.26
Diabetes 62 (3.6) 23 (4.0) 39 (3.4)
Pre-diabetes 429 (25.1) 149 (26.2) 280 (24.5)
aData are means ± SE for quantitative variables or n (%) for qualitative variables.
bHbA1c values have been indicated in accordance with both the National Glycohemoglobin Standardization Program (NGSP) and the International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) criteria.
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considered for this purpose [15]. While the 2-hour, fast-
ing glucose, and HbA1c can all be defined as continuous
statistical variables that are influenced by individual
habits, it is not well known which of these variables are
best related to the primary risk factors of diabetes [16].
At present, the FINDRISC, which is the most accurate
and widely questionnaire used in Europe, can easily
identify people with either unrecognized diabetes or
impaired glucose regulation, before any blood test needs
to be carried out [9].
During the past decade, many studies whose common
purpose was the validation of different questionnaires to
predict current or future diabetes have been published.
In all these studies, diagnoses were assessed using the
glucose-based criteria [17-19]. Although the majority of
these studies included non-invasive variables (modifiable
or not) that can be easily obtained (obesity, aging, family
and personal history), other studies used biochemical
(blood glucose, lipid profile, insulinemia, biomarkers) or
even genetic variables (polymorphisms) in an attempt to
increase their performance. Clearly, from the standpoint
of primary health are, those using non-invasive variables
are the most suitable because they simplify the task of
screening in daily clinical practice. We consider that the
target population for community prevention programs
should not be limited only to individuals with impaired
glucose tolerance, despite the strong scientific evidence
for the effectiveness of preventive measures in indivi-
duals with this diagnosis. Much work has been carried
out to develop diabetes risk scores, but most are rarely
Figure 1 Distribution of participation in the screening. Flowchart of the two screening phases, showing the distribution of participants by
Finnish Diabetes Risk Score (FINDRISC) results and the three sets of diagnostic criteria: 2-hour plasma glucose (2hPG), fasting plasma glucose
(FPG), and hemoglobin (Hb)A1c.
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used because they require blood tests that are not routi-
nely available. Furthermore, it has been shown that
using more complex variables adds little or nothing to
the overall model, and does not always improve the per-
formance of the risk score [20,21].
Issues and limitations in screening for diabetes by the
FINDRISC in primary care
The DE-PLAN-CAT cohort was prospectively recruited
for the express purpose of evaluating the FINDRISC ques-
tionnaire as an earlier detection tool for individuals at high
risk for diabetes who would then be offered a preventive
intervention. Obviously, a limitation of the present study
is that it includes only data obtained during a large screen
conducted in primary health care, not on prospective data
based on future diagnoses, which will require a longer
follow-up. In fact, the diagnosis of diabetes and pre-dia-
betes were based on only one OGTT value, not two, but
this is a commonly accepted procedure for screening large
samples. We tried first to measure the FINDRISC perfor-
mance in predicting current glucose disorders and then to
compare the results based on different sets of diagnostic
criteria. Obviously, we cannot exclude the possibility of
some selection bias. Nevertheless, the available data on the
4-year incidence of diabetes in the DE-PLAN-CAT cohort
based on repeat testing have been contributed together
Table 3 Characteristics of the participants in the second screening step (n = 1,712) by Finnish Diabetes Risk Score
(FINDRISC) classes including glucose and hemoglobin (Hb)A1c findings
Parameter FINDRISC classes Total p
<7 7 to 11 12 to 14 15 to 20 >20
Number of participants, n 98 (5.7) 475 (27.7) 416 (24.3) 633 (37.0) 90 (5.3) 1712 -
Sex, men 29 (29.6) 174 (36.6) 135 (32.5) 212 (33.5) 19 (21.1) 569 (33.2) 0.06
Age, years 55.0 ± 7.5 60.1 ± 8.2 60.4 ± 8.0 62.0 ± 8.0 61.8 ± 8.4 60.7 ± 8.2 <0.01
45-54 53 (54.1) 147 (30.9) 114 (27.4) 129 (20.4) 21 (23.3) 464 (27.1)
55-64 34 (34.7) 172 (36.2) 160 (38.5) 244 (38.5) 30 (33.3) 640 (37.4)
>65 11 (11.2) 156 (32.8) 142 (34.1) 260 (41.1) 39 (43.3) 608 (35.5)
BMI, kg/m2 23.8 ± 2.4 27.6 ± 3.9 29.7 ± 4.5 31.5 ± 4.2 33.6 ± 4.4 29.7 ± 4.7 <0.01
< 25 70 (71.4) 107 (22.5) 41 (9.9) 19 (3.0) 3 (3.3) 240 (14.0)
25-30 27 (27.6) 281 (59.2) 208 (50.0) 215 (34.0) 9 (10.0) 740 (43.2)
≥ 30 1 (1.0) 87 (18.3) 167 (40.1) 399 (62.7) 78 (86.7) 732 (42.8)
Waist circumference, cm 81.7 ± 7.7 93.2 ± 10.6 97.9 ± 10.8 101.8 ± 9.8 105.2 ± 9.6 97.4 ± 11.5 <0.01
M<94, F<80 72 (73.5) 86 (18.1) 24 (5.8) 11 (1.7) 0 (0.0) 193 (11.3)
M 94-102, F 80-88 26 (26.5) 186 (39.2) 113 (27.2) 137 (21.6) 1 (1.1) 463 (27.0)
M ≥103, F ≥89 0 (0.0) 203 (42.7) 279 (67.1) 485 (76.6) 89 (98.9) 1056 (61.7)
Systolic blood pressure, mmHg 122.8 ± 14.5 130.7 ± 15.1 132.7 ± 15.7 134.8 ± 14.9 138.3 ± 16.7 132.6 ± 15.5 <0.01
Diastolic blood pressure, mmHg 73.7 ± 7.9 77.4 ± 8.7 79.4 ± 16.8 79.7 ± 9.1 81.9 ± 9.2 78.8 ± 11.4 <0.01
FINDRISC items
Antihypertensive medication 6 (6.1) 136 (28.6) 170 (40.9) 394 (62.2) 66 (73.3) 772 (45.1) <0.01
Physical activity 81 (82.7) 389 (81.9) 296 (71.2) 416 (65.7) 36 (40.0) 1218 (71.1) <0.01
Consumption of vegetables/fruits 81 (82.7) 428 (90.1) 358 (86.1) 540 (85.3) 75 (83.3) 1482 (86.6) 0.09
History of blood glucose disorders 0 (0.0) 17 (3.6) 60 (14.4) 277 (43.8) 88 (97.8) 442 (25.8) <0.01
Family history, first degree 4 (4.1) 46 (9.7) 65 (15.6) 74 (11.7) 4 (4.4) 193 (11.3) <0.01
Family history, other degree 0 (0.0) 88 (18.5) 172 (41.3) 404 (63.8) 83 (92.2) 747 (43.6) <0.01
2-hour Plasma glucose, mmol/l 5.3 ± 2.0 6.2 ± 2.3 6.4 ± 2.6 7.4 ± 3.0 9.4 ± 3.2 6.8 ± 2.8 <0.01
Diabetes 1 (1.0) 24 (5.1) 23 (5.5) 81 (12.8) 29 (32.2) 158 (9.2)
Pre-diabetes 7 (7.1) 87 (18.3) 75 (18.0) 172 (27.2) 39 (43.3) 380 (22.2)
Fasting plasma glucose, mmol/l 4.7 ± 0.5 5.0 ± 0.8 5.1 ± 1.0 5.4 ± 1.1 6.0 ± 1.3 5.2 ± 1.0 <0.01
Diabetes 0 (0.0) 7 (1.5) 10 (2.4) 28 (4.4) 8 (8.9) 53 (3.1)
Pre-diabetes 6 (6.1) 83 (17.5) 80 (19.2) 210 (33.2) 53 (58.9) 432 (25.2)
HbA1c (NGSP),%b 5.3 ± 0.5 5.4 ± 0.5 5.4 ± 0.6 5.5 ± 0.6 5.8 ± 0.5 5.5 ± 0.6 <0.01
HbA1c (IFCC), mmol/molb 34.3 ± 5.3 35.2 ± 5.9 36.0 ± 6.2 37.1 ± 6.9 40.1 ± 5.8 36.3 ± 6.4 <0.01
Diabetes 1 (1.0) 9 (1.9) 9 (2.2) 33 (5.2) 10 (11.1) 62 (3.6)
Pre-diabetes 22 (22.4) 114 (24.0) 107 (25.7) 150 (23.7) 36 (40.0) 429 (25.1)
aData are means ± SE for quantitative variables or n (%) for qualitative variables.
bHbA1c values have been indicated in accordance with both the National Glycohemoglobin Standardization Program (NGSP) and the International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) criteria.
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with those from the derivation PREDIMED cohort to
develop a new questionnaire tailored to the needs of our
own Spanish Mediterranean setting [22].
The general profile of the participants was similar to
that of the general populaiton attending primary care.
As shown previously, women are most likely to use
these services in Spain [7], and this predominance is
similar to previous widespread trials concerning diabetes
prevention in Finland and the USA [5,6]. Similar to
these trials, the number of men in our trial was lower
than the number of women, and the proportion of men
aged over 65 years was greater than the proportion of
included women of the same age. This distribution
could perhaps explain why the risk of diabetes assessed
by the score was higher in women whereas the risk
assessed by the blood tests was higher in men.
In this regard, the age and sex distribution could be per-
ceived as another bias at work, particularly if compared
with larger population-based studies. Undoubtedly, the
main reason for this is that the protocol was conducted
under real working conditions in primary care; however
this could also be considered as an advantageous approach
for this study. Moreover, it seems that individuals identi-
fied as high risk at screening can all benefit similarly from
lifestyle intervention, regardless of age, sex, and socioeco-
nomic group [23]. In previous controlled trials, older peo-
ple seemed to benefit somewhat more than younger ones,
but men and women both had similar outcomes. Accord-
ingly, in specifying the target participant profile for
diabetes prevention in primary care, it does not seem
necessary to pay too much attention to population sub-
groups; rather, it is more important to plan properly for
consistent preventive measures [23-25].
Limitations of the FINDRISC using HbA1c as diagnostic
criterion
When estimating the overall discriminatory strength of the
questionnaire by means of the AUCs, the FINDRISC
produced values ranging from 0.72 to 0.86, at least in the
Finnish derivation samples [8,23]. The performance of the
Spanish version used in this study was 0.71 for detecting
diabetes (both 2hPG and FPG diagnosis) and 0.67 (2hPG-
based diagnosis) or 0.69 (FPG-based diagnosis) for detect-
ing all glucose metabolic abnormalities (that is, diabetes
and pre-diabetes). These figures are comparable with
those obtained in most European countries other than
Finland (validation samples), generally ranging from 0.60
to 0.80 [17-19]. Running the score on a new population
with similar but not identical features from the population
for which it was developed almost invariably leads to a
loss of performance, suggesting that the FINDRISC ques-
tionnaire, although acceptable, should be validated within
the population for which it is intended to be used.
However, almost all previous studies were carried out
using the conventional diagnostic criteria based on
glucose, and did not use the new diagnostic criteria based
on HbA1c. When HbA1c was applied as the primary diag-
nostic criterion, the AUC dropped to 0.67 (5.6% reduction
Figure 2 Distribution of test scores by diagnostic categories. Finnish Diabetes Risk Score (FINDRISC) values classified by glucose-metabolism
category (normal, pre-diabetes, diabetes), using the 2-hour plasma glucose (2hPG), fasting plasma glucose (FPG) and hemoglobin (Hb)A1c
diagnostic criteria. Data in the associated table are mean ± SD.
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in comparison with either 2-hour or fasting glucose) for
detecting diabetes, and in particular, it fell to 0.55 for
detecting all glucose abnormalities (17.9% and 20.3%
reduction, respectively). As far as we know, this is the first
estimate of a possible loss of performance of the FIN-
DRISC questionnaire if there is a widespread use of these
Figure 3 Receiver operating characteristic (ROC) curves by glucose and hemoglobin (Hb)A1c diagnosis. Receiver operating characteristic
curves for the prevalence of (A, C, E) unknown type 2 diabetes and (B, D, F) overall glucose abnormalities (diabetes and pre-diabetes) classified
by the 2-hour plasma glucose (2hPG), fasting plasma glucose (FPG) and hemoglobin (Hb)A1c diagnostic criteria.
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new proposed HbA1c-based diagnostic criteria, at least as
a screening tool in the context of a program aimed at pre-
venting diabetes.
The ROC curves indicated that a lower cut-off of 14 for
detecting diabetes or any glucose metabolic abnormality
offered the best balance in this population, irrespective to
the set of diagnostic criteria used. This cut-off is one point
lower than 15, the most commonly used point [24], but
even lower cut-off points have been considered suitable for
screening in other community-based diabetes-prevention
programs [25]. It is likely that if we had given blood tests to
all participants who answered the FINDRISC questionnaire,
the cut-off would also have increased. However, the strat-
egy we used is a realistic one to identify individuals at high
risk who might be offered a preventive intervention, rather
than being a stringent experimental study aimed at validat-
ing the scale. In our study, we found that the maximum
sensitivity and specificity of the FINDRISC were about 76%
and 52%, respectively for detecting diabetes, and 68% and
56%, respectively, for detecting all glucose abnormalities.
When diabetes was defined by a single HbA1c measure-
ment, this resulted in a small decrease in sensitivity, ranging
from 1.3% (compared with 2hPG-based diagnosis) to 1.7%
(compared with FPG-based diagnosis). For detecting all
glucose abnormalities, the use of HbA1c-based criteria led
to a greater reduction in sensitivity, ranging from 11.4%
(compared with FPG diagnosis) to 13.6% (compared with
2-hour plasma glucose diagnosis). The corresponding spe-
cificity findings also showed a reduction although this was
more moderate, reaching a maximum of 5.4%.
In contrast to population-based studies, the DE-PLAN-
CAT survey was essentially focused on a representative
sample of undiagnosed subjects in primary care, where the
likelihood of presenting glucose abnormalities obviously
increases. Leaving aside the inconvenience of using the
OGTT, both the WHO and the ADA criteria established
that in the absence of unequivocal hyperglycemia, the
results should be confirmed by repeat testing, at least in
clinical practice. Therefore, it is not surprising that about
one-third of the participants were diagnosed as having any
type of impaired glucose metabolism, as the screening was
based on a single test. In a previous work conducted in
the same population, we showed that defining diabetes by
FPG resulted in a significant decrease in prevalence com-
pared with defining diabetes by 2hPG, even in repeat tests
for those participants who agreed to the lifestyle interven-
tion [26]. In addition, a shift from glucose-based to
HbA1c-based diagnosis was also shown to reduce the
apparent diabetes prevalence, with a low overall or single
degree of overlap between diagnostic categories [26].
Implications
The decrease in performance of the FINDRISC can be
explained by the preceding validations using the glucose-
Table 4 Characteristics of the main Finnish Diabetes Risk Score (FINDRISC) cut-off points for screening-detected type 2
diabetes and glucose abnormalities (diabetes and pre-diabetes), classified by glucose and hemoglobin (Hb)A1c
diagnostic criteria.
Cut-off values n (%) Diabetesa Glucose abnormalitiesa
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Diagnostic classification by the WHO criteria (2-hour plasma glucose)
6 31 (1.8) 100.0 4.3 9.6 100.0 99.3 5.4 32.5 94.0
10 111 (6.5) 94.9 19.7 11.7 97.5 90.9 22.6 35.0 84.4
13 166 (9.7) 81.0 42.1 12.5 95.6 73.2 46.0 38.3 78.9
14 139 (8.1) 75.9 52.3 13.9 95.5 65.8 56.7 41.1 78.4
15 156 (9.1) 69.6 60.6 15.2 95.1 59.7 65.8 44.4 78.1
Diagnostic classification by the ADA criteria (fasting plasma glucose)
6 31 (1.8) 100.0 4.0 3.2 100.0 99.2 5.1 29.2 94.0
10 111 (6.5) 100.0 18.9 3.8 100.0 92.6 22.7 32.1 88.5
13 166 (9.7) 84.9 40.7 4.4 98.8 75.3 46.0 35.5 82.5
14 139 (8.1) 75.5 50.5 4.6 98.5 68.0 56.6 38.3 81.8
15 156 (9.1) 67.9 58.6 5.0 98.3 61.6 65.4 41.4 81.2
Diagnostic classification by the HbA1c-based criteria
6 31 (1.8) 98.4 4.0 3.7 98.5 97.1 4.3 29.0 79.1
10 111 (6.5) 93.5 18.8 4.2 98.7 83.9 19.2 29.5 74.8
13 166 (9.7) 77.4 40.6 4.7 98.0 62.3 40.9 29.8 73.0
14 139 (8.1) 74.2 50.5 5.3 98.1 54.4 51.3 31.0 73.6
15 156 (9.1) 69.4 58.8 5.9 98.1 46.6 59.5 31.7 73.5
ADA, American Diabetic Association; Hb, hemoglobin; NPV, negative predictive value; PPV, positive predictive value.
aData on sensitivity, specificity, PPV and NPV are percentages.
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based diagnostic criteria. A low level of diagnostic overlap
and an underestimation of diabetes prevalence using the
HbA1c mean that a number of individuals would be
moved from the diabetes category to the normal or pre-
diabetes categories. In fact, the proposed HbA1c cut-off
point for diagnosing diabetes (48 mmol/mol or 6.5%) has
resulted in minor discrepancies [27], but the cut-off point
for pre-diabetes (38 mmol/mol or 5.7%) is under discus-
sion, particularly with regard to its potential use in popula-
tion screening [27]. Both the decrease in diabetes
prevalence using the HbA1c and FINDRISC performance
could have important implications for primary healthcare-
based diabetes prevention.
Conclusions
Our recommendation is that all people attending
primary healthcare facilities should be screened for dia-
betes risk using the FINDRISC, perhaps with a lower
cut-off point in mind, or preferably using a personal
adapted score. The present study showed that the FIN-
DRISC questionnaire, although a far from ideal tool, has
a reasonably high capability of predicting current
undiagnosed diabetes and pre-diabetes as defined by
glucose-based diagnostic criteria in this cross-section of
the Spanish population. However, a shift from the
glucose-based diagnosis to the HbA1c-based diagnosis
would significantly reduce not only the estimated
diabetes prevalence but also the FINDRISC capability to
screen for glucose abnormalities. Consequently, it is
desirable that new adaptations of this score consider the
real possibility of diagnosing by the HbA1c.
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